Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat ... MarketWatch (press release) The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after 1 to 3 ... |
